The past week in medtech saw Boston Scientific (NYSE:BSX) make an interesting move in the Afib space — and much more.
Want to hear more about the week’s top news? Executive editor Chris Newmarker and Tom Salemi will discuss the week’s “Newmarker’s Newsmakers” during our DeviceTalks Weekly podcast. Without further ado, here’s this week’s MassDevice Top Five:
5. NanoVibronix device gains FDA nod for import to U.S.
UroShield is an ultrasound-based system designed for preventing bacterial colonization and biofilm on indwelling urinary catheters while also increasing antibiotic efficacy to reduce the incidence of catheter-associated urinary tract infections (CAUTI). Read the full story.
4. FDA updates adverse-event database
The agency said it now includes new adverse-event summaries, the number of events, and exemption number fields in its eMDR, eSubmitter and Manufacturer and User Facility Device Experience Database (MAUDE). Read the full story.
3. Why is there still an N95 shortage?
The nationwide shortage of N95 respirators needed by healthcare workers and others during the coronavirus pandemic shows no indications of letting up, according to an article in the Washington Post. Read the full story.
2. 12 surgical robotics companies you need to know
Intuitive Surgical (NSDQ:ISRG) pioneered robotic surgery through the early 2000s and remains the dominant player, but major companies including Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ) have big plans to enter the space and compete. Read the full story.
1. Boston Scientific may buy Afib treatment startup Farapulse
Farapulse has developed a pulsed-field ablation (PFA) system for treating atrial fibrillation (Afib) and other cardiac arrhythmias. The PFA system is designed with a sheath, a generator and catheters to ablate heart tissue through a therapeutic electric field instead of using thermal energy sources like radiofrequency ablation or cryoablation. Read the full story.